Pfizer Inc.

NYSE:PFE   1:59:30 PM EDT
40.17
+0.06 (+0.14%)
Products

U.S. FDA Accepts Pfizer’s Investigational 20-Valent Pneumococcal Conjugate Vaccine Biologics License Application For Priority Review

Published: 12/08/2020 21:41 GMT
Pfizer Inc. (PFE) - U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older.
Pfizer Inc - If Approved, Vaccine Will Help Protect Adults Against 20 Serotypes Responsible for Majority of Invasive Pneumococcal Disease and Pneumonia.
Pfizer Inc - PDUFA Goal Date for a Decision by FDA on 20vpnc Application is in June 2021.